Compass Pathways data strengthens launch prospects, says Oppenheimer
Oppenheimer maintains an Outperform rating and $20 price target on shares of Compass Pathways, telling investors in a research note that the Phase 3 COMP006 26-week data reinforce the durable efficacy of COMP360 for treatment-resistant depression, strengthening the case for a potential first FDA approval of a classical psychedelic and supporting a commercial opportunity that appears undervalued ahead of a planned Q4 NDA submission and potential 1H27 launch.
Oppenheimer maintains an Outperform rating and $20 price target on shares of Compass Pathways, telling investors in a research note that the Phase 3 COMP006 26-week data reinforce the durable efficacy of COMP360 for treatment-resistant depression, strengthening the case for a potential first FDA approval of a classical psychedelic and supporting a commercial opportunity that appears undervalued ahead of a planned Q4 NDA submission and potential 1H27 launch.